# TaiLai Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tailai-biosciences

- Industry: Healthcare Specialists
- Headquarters: Shenzhen, China
- Website: www.tailai.bio
- Total disclosed funding: $15M
- Latest round: Series A (Dec 30, 2020)
- Investors on record: 3

## About

Based in Shenzhen, China and established in 2018, TaiLai Biosciences is a biotech company engaged in the development of innovative liquid biopsy products and services for early cancer screening and diagnosis. TaiLai Biosciences' CEO, Stanley Lau, brings 40 years of experience in the pharmaceutical and healthcare industry, having held senior positions in multinational corporations such as Merck, Schering-Plough, and Baxter. The team consists of professionals with expertise in various omics fields, collaborating with top hospitals and international immunotherapy companies for research and development. In December 2020, the firm raised approximately CNY 100 million in a round of series A funding.

TaiLai Biosciences focuses on the research and development of cancer screening technologies. Their flagship product, Meta-Pan® (An'an Pan®), offers early risk warning for 14 common types of cancer in China. The company's products are designed to provide comprehensive and reliable cancer screening services, with applications in healthcare institutions, insurance organizations, and for individual consumers.

The company generates revenue by providing cancer screening services and diagnostic products to a wide range of clients, including medical institutions and individual consumers.

## Funding rounds

- Series A, Dec 30, 2020, $15M — CDH Investments, TigerYeah Capital, For Future Capital

## Investors

- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series A
- TigerYeah Capital (https://capitalatlas.ai/funds/tigeryeah-capital) — Series A
- For Future Capital (https://capitalatlas.ai/funds/for-future-capital) — Series A